JP7076579B2 - シロリムスを含む、改善された含量均一性を有する薬剤学的製剤 - Google Patents
シロリムスを含む、改善された含量均一性を有する薬剤学的製剤 Download PDFInfo
- Publication number
- JP7076579B2 JP7076579B2 JP2020564882A JP2020564882A JP7076579B2 JP 7076579 B2 JP7076579 B2 JP 7076579B2 JP 2020564882 A JP2020564882 A JP 2020564882A JP 2020564882 A JP2020564882 A JP 2020564882A JP 7076579 B2 JP7076579 B2 JP 7076579B2
- Authority
- JP
- Japan
- Prior art keywords
- sugar
- sirolimus
- calcium carbonate
- pharmaceutical preparation
- saccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
糖衣層を含むシロリムス錠剤を、以下の方法で調製した。
賦形剤を混合して最終混合物を調製した後、打錠機を用いて打錠してコア錠剤を調製した。
活性成分であるシロリムス、ポロキサマー、及び精製水を粉砕機に投入し、懸濁液を調製した。調剤容器に精製水を入れて加温した後、スクロース、ポビドン、主成分懸濁液、沈降炭酸カルシウム、微結晶セルロース、及びトコフェロールを加えてコーティング液を調製した。
実施例1~4の質量偏差試験
以下の方法で質量偏差を測定した。
市販の糖衣錠の質量偏差試験
以下の方法で、市販品である正露丸、ビサコジル錠、及びアクティナム錠に対する質量偏差を測定した。
含量均一性試験
韓国薬局方の一般試験法のうち、製剤均一性試験における含量均一性の試験方法に従って、実施例1~4の錠剤に対する含量均一性試験を行った。
1)検出器:紫外部吸光光度計(検出波長277nm)
2)カラム:Inertsil ODS-4(4.6×150mm、5μm)またはそれと同等のカラム
3)移動相:アセトニトリルと精製水の混合液(90:10)
4)カラム温度:50℃前後の一定温度
5)サンプル温度:10℃前後の一定温度
6)注入量:10μL
7)流量:1.5mL/分
Claims (11)
- シロリムスを活性成分として含み、
糖類及び炭酸カルシウムをさらに含み、糖類と炭酸カルシウムが10:1~1:1の質量比で含まれる、薬剤学的製剤。 - 前記糖類が、スクロース、ブドウ糖、乳糖、ソルビトール、マンニトール、及びキシリトールからなる群から選択される1つ以上であることを特徴とする、請求項1に記載の薬剤学的製剤。
- 前記糖類がスクロースであることを特徴とする、請求項2に記載の薬剤学的製剤。
- 糖類と炭酸カルシウムが9:1~2:1の質量比で含まれることを特徴とする、請求項1に記載の薬剤学的製剤。
- (1)コア錠剤及び(2)糖衣層を含み、
前記糖衣層がシロリムスを活性成分として含み、糖類及び炭酸カルシウムをさらに含み、糖類と炭酸カルシウムが10:1~1:1の質量比で含まれることを特徴とする、薬剤学的製剤。 - 糖類と炭酸カルシウムが9:1~2:1の質量比で含まれることを特徴とする、請求項5に記載の薬剤学的製剤。
- シロリムスが、糖衣層の総質量に対して、0.1~10質量%の量で含まれることを特徴とする、請求項5に記載の薬剤学的製剤。
- シロリムスが、糖衣層の総質量に対して、0.5~5質量%の量で含まれることを特徴とする、請求項7に記載の薬剤学的製剤。
- 以下のステップを含む、シロリムスを活性成分として含み、さらに糖類と炭酸カルシウムを10:1~1:1の質量比で含む、薬剤学的製剤の製造方法;
糖類、炭酸カルシウム、及びシロリムス懸濁液を添加してコーティング液を調製するステップ、及び
コア錠剤をコーティングパンに入れ、前記コーティング液を塗布及び乾燥させるステップ。 - 前記糖類が、スクロース、ブドウ糖、乳糖、ソルビトール、マンニトール、及びキシリトールからなる群から選択される1つ以上であることを特徴とする、請求項9に記載の薬剤学的製剤の製造方法。
- 前記糖類がスクロースであることを特徴とする、請求項10に記載の薬剤学的製剤の製造方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0058753 | 2018-05-24 | ||
KR1020180058753A KR102051804B1 (ko) | 2018-05-24 | 2018-05-24 | 시롤리무스를 포함하는 우수한 함량균일성을 갖는 약제학적 제제 |
PCT/KR2019/006098 WO2019225954A1 (en) | 2018-05-24 | 2019-05-21 | A pharmaceutical formulation with improved content uniformity comprising sirolimus |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021523928A JP2021523928A (ja) | 2021-09-09 |
JP7076579B2 true JP7076579B2 (ja) | 2022-05-27 |
Family
ID=68616026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020564882A Active JP7076579B2 (ja) | 2018-05-24 | 2019-05-21 | シロリムスを含む、改善された含量均一性を有する薬剤学的製剤 |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP7076579B2 (ja) |
KR (1) | KR102051804B1 (ja) |
CN (1) | CN112236132A (ja) |
TW (1) | TWI698239B (ja) |
WO (1) | WO2019225954A1 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090068266A1 (en) | 2007-09-11 | 2009-03-12 | Raheja Praveen | Sirolimus having specific particle size and pharmaceutical compositions thereof |
US20090130210A1 (en) | 2007-09-11 | 2009-05-21 | Raheja Praveen | Pharmaceutical compositions of sirolimus |
US20100098770A1 (en) | 2008-10-16 | 2010-04-22 | Manikandan Ramalingam | Sirolimus pharmaceutical formulations |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5985325A (en) * | 1997-06-13 | 1999-11-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
KR100612520B1 (ko) * | 2003-05-07 | 2006-08-11 | 아키나, 인크. | 신속용융 정제를 제조하기 위한 고소성 과립 |
CN1819819B (zh) * | 2003-05-07 | 2011-03-09 | 株式会社三养社 | 用于制备速熔片的高度可塑性颗粒 |
BRPI0716658A2 (pt) * | 2006-08-11 | 2015-02-10 | Panacea Biotec Ltd | Partículas para distribuição de ingredientes ativos, processo de fabricação e suas composições |
-
2018
- 2018-05-24 KR KR1020180058753A patent/KR102051804B1/ko active IP Right Grant
-
2019
- 2019-05-21 WO PCT/KR2019/006098 patent/WO2019225954A1/en active Application Filing
- 2019-05-21 CN CN201980034688.6A patent/CN112236132A/zh active Pending
- 2019-05-21 JP JP2020564882A patent/JP7076579B2/ja active Active
- 2019-05-24 TW TW108117994A patent/TWI698239B/zh active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090068266A1 (en) | 2007-09-11 | 2009-03-12 | Raheja Praveen | Sirolimus having specific particle size and pharmaceutical compositions thereof |
US20090130210A1 (en) | 2007-09-11 | 2009-05-21 | Raheja Praveen | Pharmaceutical compositions of sirolimus |
US20100098770A1 (en) | 2008-10-16 | 2010-04-22 | Manikandan Ramalingam | Sirolimus pharmaceutical formulations |
Also Published As
Publication number | Publication date |
---|---|
TWI698239B (zh) | 2020-07-11 |
JP2021523928A (ja) | 2021-09-09 |
TW202011961A (zh) | 2020-04-01 |
CN112236132A (zh) | 2021-01-15 |
KR102051804B1 (ko) | 2019-12-04 |
WO2019225954A1 (en) | 2019-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5775464B2 (ja) | 非晶質cddo−meを含有する遅延放出性経口投薬組成物 | |
ES2743699T3 (es) | Forma de dosificación oral de ketamina | |
US20230381194A1 (en) | Suspension for oral administration comprising amorphous tolvaptan | |
EP2763663B1 (en) | Pharmaceutical compositions comprising 40-o-(2-hydroxy)ethyl-rapamycin | |
RU2504362C2 (ru) | Системы доставки лекарственных веществ, включающие в себя слабоосновные лекарственные вещества и органические кислоты | |
US11331274B2 (en) | Milrinone controlled-release formulation | |
EP4082534A1 (en) | Solid preparation, and preparation method therefor and use thereof | |
KR102479497B1 (ko) | 바레니클린 서방성 제제 및 이의 제조 방법 | |
UA122224C2 (uk) | Комбінована композиція тезофензину і бета-блокатора | |
US9180198B2 (en) | Slow-release cilostazol tablet having an improved elution rate and minimal side effects | |
EP2665477B1 (en) | Modified release compositions of epalrestat or a derivative thereof and methods for using the same | |
EP3437645B1 (en) | Film-coated tablet having high chemical stability of active ingredient | |
JP7076579B2 (ja) | シロリムスを含む、改善された含量均一性を有する薬剤学的製剤 | |
KR102081176B1 (ko) | 타크로리무스를 포함하는 서방형 약제학적 제제 | |
JP2023071921A (ja) | 様々な用量のレナリドミドの経口用錠剤組成物 | |
US20210308044A1 (en) | Pharmaceutical suspension for oral dosage | |
EP2392318A1 (en) | A pharmaceutical controlled release composition of losartan | |
EP1465607B1 (fr) | Compositions pharmaceutiques a liberation modifiee | |
KR102330953B1 (ko) | 소듐-1-[6-(모르폴린-4-일)피리미딘-4-일]-4-(1h-1,2,3-트리아졸-1-일)-1h-피라졸-5-올레이트를 함유하는 제약 투여 형태 | |
KR102584268B1 (ko) | 안전성과 안정성이 개선된 피르페니돈을 포함하는 장용성 제제 및 이의 제조방법 | |
CN113521020B (zh) | 一种含有水溶性酸的瑞德西韦固体剂型 | |
BR112017018871B1 (pt) | Composição farmacêutica compreendendo metoprolol, tesofensina ou um sal farmaceuticamente aceitável dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201119 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220222 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220418 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220517 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7076579 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |